publication date: Sep. 19, 2014

html AACR.html

AACR 2014 Cancer Report: More Federal Funds Needed

The American Association for Cancer Research published its 2014 Cancer Progress Report Sept. 16, highlighting the need for greater federal investments in biomedical research.

The report is a “comprehensive educational tool that chronicles the progress that has been made against cancer…and calls on the administration and Congress to prioritize the growth of the NIH and NCI budgets,” according to AACR.

AACR estimates that cancer incidence in the U.S. will grow over the next two decades to 2.4 million, up from 1.6 million this year.

“While we are continuing to make impressive progress against cancer, the pace of that progress is being slowed due to years of declining budgets at the NIH and NCI,” said Carlos Arteaga, AACR president and professor of medicine and cancer biology at Vanderbilt-Ingram Cancer Center.

“If we are to fully realize the promise of science to transform cancer care, it will require leadership in Congress and within the administration to ensure that biomedical research in cancer becomes a major priority for our nation.”

The NIH budget, while basically remaining a flat number, has effectively shrunk by $3.5 billion over the last five years because it has not been kept pace with biomedical inflation.

According to the report:

• There are estimated to be nearly 14.5 million cancer survivors alive today in the U.S., and almost 380,000 of these individuals received their cancer diagnoses as children or adolescents.

• Between Aug. 1, 2013, and July 31, 2014, FDA approved six new anticancer therapeutics and new uses for five previously approved drugs.

Continue reading 40-35 AACR 2014 Cancer Report: More Federal Funds Needed

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.